Hauptinhalt
Publikationen Prof. Dr. Arnold Grünweller
Peer Review
2024
74. Schiffmann S, Henke M, Brünner S, Bennett A, Yagubi Y, Magari F, Parnham MJ, Grünweller A., Immune Modulatory Profile of the Pateamines PatA and Des-Methyl Des-Amino PatA. Int J Mol Sci. 25(21):11430.
73. Magari F, Messner H, Salisch F, Schmelzle SM, van Zandbergen G, Fürstner A, Ziebuhr J, Heine A, Müller-Ruttloff C, Grünweller A., Potent anti-coronaviral activity of pateamines and new insights into their mode of action. Heliyon. 10(13):e33409. (2024).
2023
72. Obermann W, …….. Grünweller A*, Taroncher-Oldenburg G. Broad anti-pathogen potential of DEAD box RNA helicase eIF4A-targeting rocaglates. Scientific Reports. 13(1):9297 (2023). (*Corresponding author)
71. Schiffmann S, Henke M, Seifert M, Ulshöfer T, Roser LA, Magari F, Wendel HG, Grünweller A, Parnham MJ. Comparing the Effects of Rocaglates on Energy Metabolism and Immune Modulation on Cells of the Human Immune System. Int J Mol Sci. 24(6):5872 (2023).
70. Gallinger TL, Obermann W, Lange-Grünweller K, Schmidt N, Haeberlein S, Grünweller A, Grevelding CG, Schlitzer M. From dithiocarbamates to branched dithiocarbazates: Compounds with potent antischistosomal activity. Arch Pharm (Weinheim). 356(3):e2200491. (2023).
2022
69. Schiffmann S, Gunne S, Ulshöfer T, Henke M, Roser LA, Schneider AK, Cinatl J, Thomas D, Schreiber Y, Wagner PV, Grünweller A*, Parnham MJ. In Vitro Safety, Off-Target and Bioavailability Profile of the Antiviral Compound Silvestrol. Pharmaceuticals. 31;15(9):1086 (2022). (*Corresponding author)
68. Rennar GA, Gallinger TL, Mäder P, Lange-Grünweller K, Haeberlein S, Grünweller A, Grevelding CG, Schlitzer M. Disulfiram and dithiocarbamate analogues demonstrate promising antischistosomal effects. Eur J Med Chem. 15;242:114641 (2022).
67. Singh K, Martinez MG, Lin J, Gregory J, Nguyen TU, Abdelaal R, Kang K, Brennand K, Grünweller A, Ouyang Z, Phatnani H, Kielian M, Wendel HG. Transcriptional and Translational Dynamics of Zika and Dengue Virus Infection.Viruses. 28;14(7):1418. (2022).
66. Obermann W, Friedrich A, Madhugiri R, Klemm P, Mengel JP, Hain T, Pleschka S, Wendel HG, Hartmann RK, Schiffmann S, Ziebuhr J, Müller C, Grünweller A*. Rocaglates as Antivirals: Comparing the Effects on Viral Resistance, Anti-Coronaviral Activity, RNA-Clamping on eIF4A and Immune Cell Toxicity. Viruses.14(3):519 (2022). (*Corresponding author)
65. Gallinger TL, Aboagye SY, Obermann W, Weiss M, Grünweller A, Unverzagt C, Williams DL, Schlitzer M, Haeberlein S. First In Silico Screening of Insect Molecules for Identification of Novel Anti-Parasitic Compounds. Pharmaceuticals. 19;15(2):119 (2022).
2021
64. Peter Ventura AM, Haeberlein S, Konopka L, Obermann W, Grünweller A, Grevelding CG, Schlitzer M. Synthesis and Antischistosomal Activity of Linker- and Thiophene-modified Biaryl Alkyl Carboxylic Acid Derivatives. Arch Pharm. (2021).
63. Müller C, Obermann W, Karl N, Wendel HG, Taroncher-Oldenburg G, Pleschka S, Hartmann RK, Grünweller A*, Ziebuhr J. The rocaglate CR-31-B (-) inhibits SARS-CoV-2 replication at non-cytotoxic, low nanomolar concentrations in vitro and ex vivo. Antiviral Res. 186 (2021). (*Corresponding author)
62. Wiegard JC, Schlüter AC, Burenina OY, Kubareva EA, Klug G, Grünweller A, Hartmann RK. Northern blot detection of tiny RNAs. Methods in Mol Biol; 9(3):540 (2021).
61. Taroncher-Oldenburg G, Müller C, Obermann W, Ziebuhr J, Hartmann RK, Grünweller A*. Targeting the DEAD-Box RNA Helicase eIF4A with Rocaglates - A Pan-Antiviral Strategy for Minimizing the Impact of Future RNA Virus Pandemics. Microorganisms (2021), 9(3), 540; (*Corresponding author)
2020
60. Bach S, Demper J-C, Grünweller A, Becker S, Biedenkopf N, Hartmann R.K. Regulation of VP30-dependent transcription by RNA sequence and structure in the genomic Ebola virus promoter. J Virol. 186:105012 (2020).
59. Peiffer K-H, …. Grünweller A, ….. Hildt E. Quadruple mutation GCAC1809-1812TTCT acts as a biomarker in healthy European HBV carriers. JCI insight. 5(22):e135833 (2020).
58. Blum L, Geisslinger G, Parnham MJ, Grünweller A, Schiffmann S. Natural antiviral compound silvestrol modulates human monocyte‐derived macrophages and dendritic cells. J Cell Mol Med. 24(12), (2020).
57. Müller C, Obermann W, Schulte FW, Lange-Grünweller K, Oestereich L, Elgner F, Glitscher M, Hildt E, Singh K, Wendel HG, Hartmann RK, Ziebuhr J, Grünweller A.* Comparison of broad-spectrum antiviral activities of the synthetic rocaglate CR-31-B (-) and the eIF4A-inhibitor Silvestrol. Antiviral Res. 175 :104706 (2020). (*Corresponding author)
56. Bach S, Biedenkopf N, Grünweller A, Becker S, Hartmann RK. Hexamer phasing governs transcription initiation in the 3'-leader of Ebola virus. RNA 26(4), 439-453, (2020).
2019
55. Kronschnabl P, Grünweller A, Hartmann RK, Aigner A, Weirauch U. Inhibition of PIM2 in liver cancer decreases tumor cell proliferation in vitro and in vivo primarily through modulation of cell cycle progression. Int. J. Oncol. 56(2), 448-459, (2019).
54. Peter Ventura AM, Haeberlein S, Lange-Grünweller K, Grünweller A, Hartmann RK, Grevelding CG, Schlitzer M. Development of biarylalkyl carboxylic acid amides with improved antischistosomal activity. ChemMedChem. 14(21), 1856-1862, (2019).
53. Kellershohn J, Thomas L, Grünweller A, Hartmann RK, Hardt M, Vilcinskas A, Grevelding CG, Haeberlein S. Insects in anthelminthics research: lady beetle-derived harmonine affects survival, reproduction and stem cell proliferation of Schistosoma mansoni. PLoS Negl Trop Dis 13(3), (2019).
2018
52. Henss L, Scholz T, Grünweller A, Schnierle B. Silvestrol inhibits Chikungunja Virus Replication. Viruses. 10(11), 592 (2018).
51. Glitscher M, Himmelsbach K, Woytinek K, Johne R, Reuter A, Spiric J, Schwaben L, Grünweller A, Hildt E. Inhibition of Hepatitis E Virus Spread by the Natural Compound Silvestrol. Viruses. 2;10(6) (2018).
50. Elgner F, Sabino C, Basic M, Ploen D, Grünweller A, Hildt E. Inhibition of Zika Virus Replication by Silvestrol.Viruses. 27;10(4) (2018).
49. Janga H, Aznaourova M, Boldt F, Damm K, Grünweller A, Schulte LN. Cas9-mediated excision of proximal DNaseI/H3K4me3 signatures confers robust silencing of microRNA and long non-coding RNA genes. PLoS One. Feb 16;13(2):e0193066. (2018).
48. Müller C, Schulte FW, Lange-Grünweller K, Obermann W, Madhugiri R, Pleschka S, Ziebuhr J, Hartmann RK, Grünweller A.* Broad-spectrum antiviral activity of the eIF4A inhibitor silvestrol against corona- and picornaviruses. Antiviral Research 150:123-129 (2018). (*Corresponding author)
2017
47. Biedenkopf N, Lange-Grünweller K, Schulte FW, Weißer A, Müller C, Becker D, Becker S, Hartmann RK, Grünweller A.* The natural compound Silvestrol is a potent inhibitor of Ebola virus replication. Antiviral Research 137:76-81, (2017). (*Corresponding author)
46. Pelaz B, ….Grünweller A, …Parak W. Diverse applications of nanomedicine. ACS Nano (2017), 11(3):2313-2381.
2016
45. Biedenkopf N, Schlereth J, Grünweller A, Becker, S, Hartmann RK. RNA-binding of Ebola virus VP30 is essential for activating viral transcription. J Virol. 90:7481-96, (2016).
44. Schlereth J, Grünweller A, Biedenkopf N, Becker S, Hartmann RK. RNA binding specificity of Ebola virus transcription factor VP30. RNA Biol. 13(9):783-98, (2016).
43. Mäder P, Blohm AS, Quack T, Lange-Grünweller K, Grünweller A, Hartmann RK, Grevelding CG, Schlitzer M. Biarylalkyl Carboxylic Acid Derivates As Novel Antischistosomal Agents. ChemMedChem. 11:1459-68, (2016).
2015
42. Damm K, Bach S, Müller K, Klug G, Burenina O.Y, Kubareva EA, Grünweller A, Hartmann RK. Improved northern-blot detection of small RNAs using EDC crosslinking and DNA/LNA probes. Methods in Mol Biol. 1296:41-51, (2015).
41. Damm K, Bach S, Müller K, Klug G, Burenina O.Y, Kubareva E.A, Grünweller A, Hartmann RK. Impact of RNA isolation protocols on RNA detection by northern blotting. Methods in Mol Biol.1296:29-38, (2015).
2013
40. Thomas M, Lange-Grünweller K, Hartmann D, Golde L, Schlereth J, Streng, Aigner A, Grünweller A,* Hartmann RK.* Analysis of Transcriptional Regulation of the Human miR-17-92 Cluster; Evidence for Involvement of Pim-1. Int J Mol Sci. 14(6):12273-96, (2013). (*Corresponding authors)
39. Weirauch U, Beckmann N, Thomas M, Grünweller A, Huber K, Bracher F, Hartmann R.K, Aigner A. Functional role and therapeutic potential of the Pim-1 kinase in colon carcinoma. Neoplasia 15(7):783-94, (2013).
38. Weirauch U, Grünweller A, Cuellar L, Hartmann RK, Aigner A. U1 adaptors for the therapeutic knockdown of the oncogene Pim-1 kinase in glioblastoma. Nucleic Acids Therapeutics 23(4):264-72, (2013).
2012
37. Thomas M, Lange-Grünweller K, Weirauch U, Dayyoub E, Bakowsky U, Aigner A, Hartmann RK,* Grünweller A.* PEI-complexed LNA antiseeds as miRNA inhibitors. RNA Biol. 9(8):1088-1098, (2012). (*Corresponding authors)
36. Thomas M, Lange-Grünweller K, Weirauch U, Gutsch D, Aigner A, Grünweller A,* Hartmann RK.* The proto-oncogene Pim-1 is a target of miR-33a. Oncogene 31(7):918-28, (2012). (*Corresponding authors)
2011
35. Ibrahim A.F, Weirauch U, Thomas M, Grünweller A, Hartmann RK, Aigner A. MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Research 71(15):5214-24, (2011).
2010
34. Beckmann BM, Grünweller A, Weber MH, Hartmann RK. Northern blot detection of endogenous small RNAs (~14 nt) in bacterial total RNA extracts. Nucleic Acids Res. 38(14):e147, (2010).
2009
33. Grünweller A, Hartmann RK. Expanding RNA silencing approaches by U1 adaptors. ChemBioChem. 10, 1599-601, (2009).
2007
32. Christoph T, Gillen C, Mika J, Grünweller A, et al. Antinoceptive effect of antisense oligonucleotides against VR1/TRPV1. Neurochem. Int. 50, 281-290, (2007).
31. Grünweller A,* Hartmann RK. Locked nucleic acid oligonucleotides. The next generation of antisense agents? Biodrugs. 21, 235-243, (2007). (*Corresponding author)
2006
30. Christoph T, Grünweller A.* Mika J, et al. Silencing of vanilloid receptor TRPV1 by RNAi reduces neuropathic and visceral pain in vivo. Biochem Biophys Res Commun. 350(1):238-43, (2006). (* gleichberechtigt mit Erstautor)
2005
29. Schubert S., Grünweller A, Erdmann VA, Kurreck, J. Local RNA target structure influences siRNA efficacy: 2. Systematic analysis of intentionally designed binding regions. J. Mol. Biol. 348, 883-893, (2005).
28. Grünweller A,* Hartmann RK. RNA interference as a gene-specific approach for molecular medicine. Curr. Med. Chem. 12, 3143-3161, (2005). (*Corresponding author)
2003
27. Grünweller A, Gillen C., Erdmann VA, Kurreck, J. Cellular uptake and localisation of a Cy3-labelled siRNA specific for the serine/threonine kinase Pim-1. Oligonucleotides 13, 345-352, (2003).
26. Grünweller A, Wyzko E, Biebe, B, Jahnel R, Erdmann VA, Kurreck, J. Comparison of different antisense strategies in mammalien cells using locked nucleic acids, 2`-O-methyl RNA, phosphorothioates and small interfering RNA. Nucleic Acids Res. 31(12):3185-93, (2003).
2002
25. Grünweller A, Ehrenhofer-Murray AE. A novel yeast silencer. The 2µ origin of Saccharomyces cerevisiae has HST3-, MIG1- and SIR-dependent silencing activity. Genetics. 162(1):59-71, (2002).
2000
24. Kruse C, Willkomm DK, Grünweller A, Vollbrandt T, Sommer S, Pfeiffer T, Brinkmann J, Hartmann RK, Müller PK. Export and transport of tRNA are coupled to a multi-protein complex. Biochem.J. 346 Pt1,107-115, (2000).
1999
23. Krützfeldt J, Grünweller A, Raasch W, Drenckhan M, Klein HH. Microtiter well assays for protein tyrosin phosphatase activities directed against phosphorylated insulin receptor or insulin receptor substrate-1. Anal.Biochem. 271(1):97-99, (1999).
1998
22. Kruse C, Emmrich J, Rumpel E, Klinger MHF, Grünweller A, Rohwedel J., Krammer H-J, Kühnel W, Müller, PK. Production of trypsin by cells of the exocrine pancreas is paralleled by the expression of the KH-protein vigilin. Exp.Cell Res. 239,111-118, (1998).
21. Kruse C, Grünweller A, Willkomm DK, Pfeiffer T, Hartmann RK, Müller PK. tRNA is entrapped in similar but distinct nuclear and cytoplasmic ribonucleoprotein complexes both of which contain vigilin and elongation factor1a. Biochem.J. 329, 615-621, (1998).
1997
20. Grünweller A,* Purschke WG, Kügler S, Kruse C, Müller PK. The chicken vigilin gene: A distinctive pattern of hypersensitive sites is characteristic for its transciptional activity. Biochem.J. 326, 601-607, (1997). (*Corresponding Author)
19. Grünweller A,* Müller PK. Low background and short exposure times in the mapping of DNaseI-hypersensitive sites using digoxigenin-labelled probes. Anal.Biochem. 247, 172-175, (1997). (*Corresponding Author)
1996
18. Kruse C, Grünweller A, Notbohm H, Kügler S, Purschke WG, Müller PK. Evidence for a novel cytoplasmic tRNA-protein complex containing the KH-multidomain protein vigilin. Biochem.J. 320, 247-252, (1996).
17. Kügler S, Grünweller A, Probst C, Klinger M, Müller PK, Kruse C. Vigilin contains a functional nuclear localisation signal and is present both in the cytoplasm and the nucleus. FEBS Lett. 328, 330-334, (1996).
Übersichtsartikel
16. Grünweller A,* Hartmann RK.* Chemical modifications of nucleic acids as a key technology for the development of RNA-based therapeutics. Die Pharmazie 71, 8-16, (2016). (*Corresponding authors)
15. Grünweller A,* Hartmann RK.* Chemische Nukleinsäure-Modifikationen als Schlüsseltechnologie für die Entwicklung RNA-basierter Therapiestrategien. Pharmakon 04/2015 (2015). (*Corresponding authors)
14. Jäschke A, Micura R, Grünweller A, Hartmann RK, Helm M, Liebl W, Merkel L, Budisa N, Sundermann U, Kushnir S, Schulz F. Trendbericht Biochemie 2010: Nukleotidmodifikationen. Nachrichten aus der Chemie. 59, 297-318, (2011).
13. Grünweller A, Schubert S, Kurreck J. Stoppt den Boten! Antisense-, DNA Enzym- und RNA Interferenz-Strategien in der Molekularen Medizin. Bioforum 27, 46-47, (2004).
Buchbeiträge / Rezensionen / Editorials
12. Grünweller A, Hartmann RK. Silvestrol: a potential future drug for acute Ebola infection, Editorial, Future Virology, 11, 243-245 (2017).
11. Grünweller A, Lange-Grünweller K, Schulte FW, Hartmann RK. Silvestrol: Ein pflanzlicher Naturstoff mit antiviraler Wirkung. Pharmakon, 2, 93-94 (2017).
10. Hartmann RK, Grünweller A, Strecker T. Persistence of Ebola virus in the semen of survivors. Editorial. Public Health and Emergency (2016).
9. Grünweller A. Molecular Medicine - An Introduction by Jens Kurreck und Cy A. Stein. Rezension. Biospektrum 05 (2016).
8. Beckmann BM, Grünweller A, Hartmann RK. Northern blot detection of small RNAs. Handbook of RNA Biochemistry. Wiley-VCH. Edited by R.K. Hartmann, A. Bindereif, A. Schön and E. Westhof. Second Edition Vol 1, 89-103, (2013).
7. Bramsen JB, Grünweller A, Hartmann RK, Kjems J. Using chemical modification to enhance siRNA performance. Handbook of RNA Biochemistry. Wiley-VCH. Edited by R.K. Hartmann, A. Bindereif, A. Schön and E. Westhof. Second Edition Vol 2, 1243-1277, (2013).
6. Barduhn A, Ehrenhofer-Murray AE.; Geissenhöner A, Grünweller A, Irlbacher H, Kasulke D, Marchfelder U. Meijsing SH. Schaper S, Seitz S. Mechanismen der transkriptionellen Genrepression in der Hefe Saccharomyces cerevisiae. In: Jahrbuch der Max-Planck-Gesellschaft, pp. 175-178 (Ed. der Max-Planck-Gesellschaft, G.). Vandenhoeck & Ruprecht, Göttingen (2002).
Erteilte / angemeldete Patente
5. Broad-spectrum Antiviral Activity of eIF4a Inhibitors. PCT Application No. PCT/US2021/019295, filed on February 23, 2021; Wendel H-G, Grünweller A.
4. Usage of Silvestrol, Episilvestrol and Silvestrol analoga for the treatment of viral infections caused by viruses with cap-dependent translation. EP17193511.7A
AK Grünweller*/Hartmann, AK Becker, AK Ziebuhr, submitted Januar 2016 (*Melder der Erfindung). Publication of EP3305290A1 04.11.2018. Patent erteilt Nov 2022
3. Grünenthal GmbH; Erdmann VA, Grünweller A, Kurreck J, Christoph T, Gillen C. Pim-1 specific dsRNA compounds. (WO/2005/033310) (2005).
2. Schubert S, Kurreck J, Erdmann VA, Gillen C, Christoph T, Grünweller A. (2004) New DNA type 10-23 enzyme, useful for treating e.g. pain, and related short interfering RNA, directed against the vanillin receptor or picorna viruses, contains specific nucleotide modifications for improved stability. Patent Number(s): WO2004042046-A2; DE10322662-A1; AU2003288006-A1; EP1556486-A2; AU2003288006-A8; US2006122136-A1; EP1556486-B1; DE50312344-G; WO2004042046-A3
1. Altan O, Kurreck J, Erdman, VA, Grünweller A. New oligonucleotides directed against PIM1 kinase, useful for treating, e.g. pain, urinary incontinence, tumors and inflammation, by gene therapy. (2003/2004). Patent Number(s): WO2003106681-A2; AU2003242678-A1; DE10226702-A1; AU2003242678-A8; WO2003106681-A3